Skip to main content

Patient Representative Committee

The patient voice in clinical trial research

Canadian Cancer Trials Group (CCTG) recognizes the value and importance of engaging patients, including the patient voice in all aspects of the clinical trial life-cycle. Integrating the patient perspective into the CCTG’s overall strategic agenda ensures the research agenda has the greatest impact on cancer patients in Canada and around the world.

CCTG has implemented a model of dedicated public and patient involvement by including the Patient Representative, who are patient volunteers recruited to disease site committees similar to academic committee members with a three year extendable term.

  • The role of the CCTG Patient Representative has evolved to integrate the patient perspective into many steps of the research process with the aim of:
    • research questions that matter to patients, and
    • improved accrual
  • CCTG is committed to implementing best practices and materials to foster and facilitate patient engagement

If you are looking for more information about the CCTG Patient Representative Committee please contact Yvonne Murray, Patient Engagement Lead for information.

CCTG is currently looking for volunteers for these roles: 

For more information about current committee openings please contact Nancy Dusharm.

Priorities in cancer research

CCTG Patient Representatives participated in a facilitated workshop session to identify six research topics most important to cancer patients and caregivers. For the results >


CCTG Patient Representative Committee

workshop on patient engagement in clinical trials

Spring Meeting 2025 - Engaging Patient Representatives in CCTG Clinical Trials

If you are attending the CCTG Spring Meeting #CCTG2025 don't forget to drop by the open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday April 25, 10:30-12pm in the Seymour room at the Chelsea Hotel.

More >>
 
CCS Breakthrough Grant awarded for The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT):

CCS Breakthrough Grant awarded for The Canadian Network for Psychedelic-Assisted Cancer Therapy

A new national initiative as been funded by the Canadian Cancer Society, through their Breakthrough Team Grant competition.

More >>
 
SC30 RATIONAL: Role of Antibiotic Therapy or Immunoglobulin On iNfection in hAematoLogy

CIHR funding announced to investigate preventative treatments for infections in patients with hematologic cancer patients with low immune function

The CCTG SC30 (RATIONAL) trial has been successfully funded through the CIHR fall competition for nearly $1.2 million over four years.

More >>
 
The innovative ME17 melanoma trial has opened to enrollment

The innovative ME17 melanoma trial has opened to enrollment

One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.

More >>